Tips from Other Journals
Mechanical Reperfusion for Patients with MI
FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.
FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.
Am Fam Physician. 2004 May 15;69(10):2461.
Thrombolytic therapy is the coronary artery reperfusion method most commonly used in patients with acute ST-segment elevation myocardial infarction (STEMI). It is unknown whether immediate mechanical reperfusion (IMR) improves outcomes in patients with STEMI who have contraindications to thrombolytic reperfusion therapy. In this study, Grzybowski and colleagues investigated whether IMR provides a mortality benefit in patients with STEMI who are ineligible for thrombolysis.
The study included patients from the National Registry of Myocardial Infarction. Participants were eligible if they had electrocardiographic changes that made them candidates for thrombolytic therapy (defined as STEMI or presumed new left bundle branch block), if they had symptom onset within the previous 12 hours, and if they had contraindications to thrombolytic therapy. Eligible patients were divided into two groups: those who did and those who did not receive IMR (defined as percutaneous coronary intervention or coronary bypass graft surgery within 12 hours of symptom onset). Because this assignment was not random, the authors made statistical adjustments to account for potentially confounding factors and selection biases.
Of the 19,917 patients who were eligible for the study, 4,705 (23.6 percent) received IMR. Overall, 5,173 patients (25.9 percent) died in the hospital. The use of IMR was statistically significantly associated with reduced mortality in all unadjusted and adjusted analyses. All statistical models were consistent with this finding except for one, which categorized patients by quintile and showed no mortality difference in the first quintile.
In this study, patients with acute STEMI and contraindications to thrombolytic therapy had reductions in mortality associated with IMR treatment of 63.7 and 45.8 percent, depending on the statistical model. Because only 23.6 percent of eligible patients received IMR, the authors suggest that increased use of IMR treatment potentially could reduce mortality in patients with contraindications to thrombolytic therapy; however, such intervention likely would require prehospital diversion of eligible patients to IMR-capable facilities. This study did not identify subgroups of eligible patients who were most likely to benefit from IMR treatment.
Grzybowski M, et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy. A propensity analysis. JAMA. October 8, 2003;290:1891–8.
Copyright © 2004 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions